Location :
320 Logue Ave
Mountain View,
VA
94043
USA
Cellecta’s primary aim is to develop advanced high-throughput RNAi and peptide
technologies and their applications for the discovery and functional
characterization of novel therapeutic targets and drugs. We offer highly
customized contract research services using advanced lentiviral technology,
including HT sequencing-based shRNA library screens; HT functional
validation of shRNA; custom shRNA library construction; custom stable
reporter, overproducer, or knockdown cell lines; and HT screening for
bioactive peptides. With more than 6 years of experience in HT functional
screening, our scientists have developed the most advanced technology
available in collaboration with opinion leaders and with funding from nine
NIH SBIR grants.
Posters